MK0653C in High Cardiovascular Risk Patients With High Cholesterol (Switch Study)(MK-0653C-162)
Status:
Completed
Trial end date:
2012-10-01
Target enrollment:
Participant gender:
Summary
This study will compare the lipid-altering efficacy and safety of switching to
co-administration of ezetimibe and atorvastatin versus treatment with atorvastatin or
rosuvastatin in high cardiovascular risk patients with hypercholesterolemia who have not
achieved specified low-density lipoprotein cholesterol (LDL-C) levels. The primary hypothesis
is that the co-administration of ezetimibe 10 mg and atorvastatin 10 mg will be superior to
both atorvastatin 20 mg and rosuvastatin 10 mg with respect to the percentage reduction in
low-density lipoprotein-cholesterol (LDL-C) after 6 weeks of treatment.